CRVS
Corvus Pharmaceuticals Inc.
$8.04
+$0.28(+3.61%)
59
Overall
50
Value
90
Tech
39
Quality
Market Cap
$437.40M
Volume
1.89M
52W Range
$2.54 - $10.00
Target Price
$15.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $-37.0M | $-56.5M | $49.2M | $48.9M | $43.8M | $38.6M | $32.6M | $23.4M | $27.5M | ||
| Research & Development | $29.4M | $46.3M | $38.6M | $38.0M | $31.8M | $29.1M | $24.5M | $16.5M | $19.4M | ||
| Research Expense | $29.4M | $46.3M | $38.6M | $38.0M | $31.8M | $29.1M | $24.5M | $16.5M | $19.4M | ||
| Selling, General & Administrative | $7.6M | $10.2M | $10.6M | $10.9M | $11.9M | $9.5M | $8.1M | $6.9M | $8.2M | ||
| General & Administrative Expenses | $7.6M | $10.2M | $10.6M | $10.9M | $11.9M | $9.5M | $8.1M | $6.9M | $8.2M | ||
| Salaries & Wages | -- | $-6.2M | $-7.1M | -- | -- | -- | $2.7M | $2.1M | $3.0M | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | $500.0K | $400.0K | $200.0K | $100.0K | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | $500.0K | $400.0K | $200.0K | $100.0K | ||
| Other Operating Expenses | -- | -- | $-49.2M | $-446.0K | $-10.3M | $-347.0K | $-216.0K | $-222.0K | $-296.0K | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-37.0M | $-56.5M | $-49.2M | $-48.9M | $-43.8M | $-38.6M | $-32.6M | $-23.4M | $-27.5M | ||
| EBITDA | $-36.4M | $-55.7M | $-48.4M | $-48.1M | $-43.1M | $-38.2M | $-40.9M | $-26.9M | $-62.2M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $15.0K | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | -- | -- | -- | -- | -- | -- | $-654.0K | $-1.6M | -- | ||
| Gain on Sale of Securities | -- | -- | -- | -- | $-234.0K | $-4.8M | $-10.0M | $1.6M | $1.8M | ||
| Other Income/Expense | -- | -- | -- | -- | $-37.2M | $4.8M | $-9.4M | $3.6M | $34.7M | ||
| Other Special Charges | -- | -- | -- | -- | -- | -- | -- | $78.0K | $-33.4M | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-37.0M | $-56.5M | $-49.2M | $-48.9M | $-43.8M | $-38.6M | $-41.3M | $-27.0M | $-62.3M | ||
| Pre-Tax Income | $-37.0M | $-56.5M | $-49.2M | $-48.9M | $-6.5M | $-43.5M | $-41.3M | $-21.7M | $-59.1M | ||
| NET INCOME | |||||||||||
| Net Income | $-36.4M | $-55.7M | $-46.9M | $-46.7M | $-6.0M | $-43.2M | $-41.3M | $-27.0M | $-62.3M | ||
| Net Income (Continuing Operations) | $-36.4M | $-55.7M | $-46.9M | $-46.7M | $-6.0M | $-43.2M | $-41.3M | $-27.0M | $-62.3M | ||
| Net Income (Discontinued Operations) | $-36.4M | $-55.7M | $-46.9M | $-46.7M | $-6.0M | $-43.2M | $-41.3M | $-27.0M | $-62.3M | ||
| Net Income (Common Stockholders) | $-36.4M | $-55.7M | $-46.9M | $-46.7M | $-6.0M | $-43.2M | $-41.3M | $-27.0M | $-62.3M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $-58.5M | ||
| TOTALS | |||||||||||
| Total Expenses | $-37.0M | $-56.5M | $49.2M | $48.9M | $43.8M | $38.6M | $32.6M | $23.4M | $27.5M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $15.4M | $20.5M | $27.5M | $29.3M | $29.5M | $41.9M | $46.6M | $48.0M | $61.0M | ||
| Average Shares Outstanding (Diluted) | $15.4M | $20.5M | $27.5M | $29.3M | -- | $41.9M | $46.6M | $48.0M | $61.0M | ||
| Shares Outstanding | $74.5M | $74.5M | $29.3M | $74.5M | $38.3M | $46.6M | $46.6M | $49.0M | $68.1M | ||
| Basic EPS | -- | -- | -- | $-1.59 | $-0.20 | $-1.03 | $-0.89 | $-0.56 | $-1.02 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-1.59 | $-0.20 | $-1.03 | $-0.89 | $-0.56 | $-1.02 | ||
| Diluted EPS | $-2.36 | $-2.72 | $-1.71 | $-1.59 | $-0.20 | $-1.03 | $-0.89 | $-0.56 | $-1.02 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-1.71 | -- | -- | $-1.03 | $-0.89 | $-0.56 | $-1.02 | ||
| OTHER METRICS | |||||||||||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | -- | $-5.3M | $-3.2M | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | -- | $-5.3M | $-3.2M | ||
| Gain On Sale Of Business | -- | -- | -- | -- | $37.5M | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | $22.0K | -- | $5.0K | ||
| Net Income From Other Gains Losses | $601.0K | $861.0K | $2.3M | $2.2M | $540.0K | $185.0K | -- | -- | -- | ||
| Other Gand A | $7.6M | $10.2M | $10.6M | $10.9M | $11.9M | $9.5M | $8.1M | $6.9M | $8.2M | ||
| Rent And Landing Fees | $7.6M | $10.2M | $-748.0K | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRVS | $8.04 | +3.6% | 1.89M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Corvus Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW